Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Cancer Survivor Study
Brief Summary: The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, who are at increased risk of late-occurring adverse health outcomes. A group of sibling controls will be identified and data collected for comparison purposes.


Options:
A: Intervention Type: DRUG; Name: asparaginase (E. Coli); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: asparaginase (Erwina); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dexrazoxane; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (once daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: cranial radiation (twice-daily fractionation); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Intrathecal chemotherapy without radiation; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Biological: filgrastim, Drug: cyclophosphamide, Drug: dexrazoxane hydrochloride, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: prednisone, Drug: vincristine sulfate, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: dexrazoxane hydrochloride; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Ancillary-Correlative (laboratory biomarker analysis); Type: N/A; Interventions: Other: Assessment of Therapy Complications, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Assessment of Therapy Complications; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Ancillary-Correlative (laboratory biomarker analysis)
D: Arm Label: Cancer survivors; Type: N/A; Interventions: N/A | Arm Label: Sibling Controls; Type: N/A; Interventions: N/A

Answer: D